- Blarcamesine
-
- $40.00
-
2026-05-11
- CAS:195615-83-9
- Purity: 99.87%
- Supply Ability: 10g
|
| | AVex-73 Basic information |
| Product Name: | AVex-73 | | Synonyms: | AVex-73;AE38;AE37;1-(2,2-diphenyloxolan-3-yl)-N,N-dimethylmethanamine;CS-2603;3-Furanmethanamine, tetrahydro-N,N-dimethyl-2,2-diphenyl-;Blarcamesine (Anavex-2-73);ANAVEX-2-73(Blarcamesine) | | CAS: | 195615-83-9 | | MF: | C19H23NO | | MW: | 281.39 | | EINECS: | | | Product Categories: | APIS | | Mol File: | 195615-83-9.mol |  |
| | AVex-73 Chemical Properties |
| solubility | DMF: 30 mg/ml
DMSO: Slightly soluble
Ethanol: 30 mg/ml | | form | Solid | | color | White to off-white |
| | AVex-73 Usage And Synthesis |
| Uses | Blarcamesine is an orally bioavailable Sigma-1 receptor agonist and muscarinic receptor modulator, with anticonvulsant, anti-amnesic, neuroprotective and antidepressant properties. Blarcamesine ameliorates neurologic impairments in a mouse model of Rett syndrome[1]. | | in vivo | Blarcamesine (10 mg/kg, 30 mg/kg; p.o.; daily; for 6.5 weeks) ameliorates motor deficits in Mecp2 HET mice with chronic administration[1].
Blarcamesine ameliorates acoustic startle deficit in Mecp2 HET mice[1].
Blarcamesine reverses deficits in visual acuity in older Mecp2 HET mice using the optokinetic response[1].
Blarcamesine produces minimal effects on body weight gain in Mecp2 HET mice[1].
| Animal Model: | Female Mecp2tm1.1Bird/J HET (C57 background) mice[1] | | Dosage: | 10 mg/kg, 30 mg/kg | | Administration: | Oral administration, daily, for 6.5 weeks | | Result: | Reverse the deficits observed in the HET animals. |
| | IC 50 | Sigma 1 Receptor | | References | [1] Walter E Kaufmann, et al. ANAVEX2-73 (Blarcamesine), a Sigma-1 Receptor Agonist, Ameliorates Neurologic Impairments in a Mouse Model of Rett Syndrome. Pharmacol Biochem Behav . 2019 Dec;187:172796. DOI:10.1016/j.pbb.2019.172796
[2] VALENTINE LAHMY. Mitochondrial protection by the mixed muscarinic/σ1 ligand ANAVEX2-73, a tetrahydrofuran derivative, in Aβ25-35 peptide-injected mice, a nontransgenic Alzheimer’s disease model.[J]. Frontiers in Cellular Neuroscience, 2015: 463. DOI: 10.3389/fncel.2014.00463
[3] VALENTINE LAHMY. Blockade of Tau Hyperphosphorylation and Aβ1–42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic and σ1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer’s Disease[J]. Neuropsychopharmacology, 2013, 38 9: 1706-1723. DOI: 10.1038/npp.2013.70 |
| | AVex-73 Preparation Products And Raw materials |
|